Document Type
Article
Publication Date
2019
Keywords
Ganglioside GM1, monosialotetrahexosylganglioside, stroke
Digital Object Identifier (DOI)
https://doi.org/10.1177/0963689718822782
Abstract
Ganglioside GM1 is a member of the ganglioside family which has been used in many countries and is thought of as a promising alternative treatment for preventing several neurological diseases, including cerebral ischemic injury. The therapeutic effects of GM1 have been proved both in neonates and in adults following ischemic brain damage; however, its clinical efficacy in patients with ischemic stroke is still uncertain. This review examines the recent knowledge of the neuroprotective properties of GM1 in ischemic stroke, collected in the past two decades. We conclude that GM1 may have potential for stroke treatment, although we need to be cautious in respect of its complications.
Rights Information
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
Was this content written or created while at USF?
Yes
Citation / Publisher Attribution
Cell Transplantation, v. 28, issue 6, p. 657-661
Scholar Commons Citation
Zhang, Wenchao; Krafft, Paul R.; Wang, Tianlong; Zhang, John H.; Li, Li; and Tang, Jiping, "Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review" (2019). Neurosurgery and Brain Repair Faculty Publications. 44.
https://digitalcommons.usf.edu/nbr_facpub/44
